Doksazosyna w postaci doustnego systemu terapeutycznego u pacjenta z nadciśnieniem tętniczym Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2023
Słowa kluczowe:
doksazosyna, antagoniści receptorów α-adrenergicznych, nadciśnienie tętnicze
##plugins.themes.bootstrap3.article.main##
Abstrakt
W ostatnich latach wyzwaniem stała się terapia pacjentów z zespołem metabolicznym, który jest czynnikiem ryzyka powikłań sercowo-naczyniowych. Obiecującym kierunkiem badań w kontekście pacjentów z łagodnym przerostem gruczołu krokowego oraz ze współistniejącym zespołem metabolicznym okazała się doksazosyna – selektywny antagonista receptorów α-adrenergicznych. Opracowano nowy preparat doksazosyny w postaci doustnego systemu terapeutycznego w celu poprawy profilu farmakokinetycznego oraz zmniejszenia lub wyeliminowania konieczności dostosowywania dawki i ryzyka przedawkowania. Zgodnie z aktualnymi wytycznymi doksazosyna zajmuje ważną pozycję w leczeniu opornego nadciśnienia tętniczego.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Postuła , M. (2023). Doksazosyna w postaci doustnego systemu terapeutycznego u pacjenta z nadciśnieniem tętniczym . Medycyna Faktów , 16(1(58), 107-110. https://doi.org/10.24292/01.MF.0123.19
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Cubeddu LX, Fuenmayor N, Caplan N et al. Clinical pharmacology of doxazosin in patients with essential hypertension. Clin Pharmacol Ther. 1987; 41(4): 439-49.
2. Fulton B, Wagstaff A, Sorkin E. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs. 1995; 49: 295-320.
3. Chung M, Vashi V, Puente J et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999; 48: 678-87.
4. Andersson PE, Johansson J, Berne C et al. Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens. 1994; 8: 219-26.
5. Kageyama S, Yamamoto J, Mimura A et al. Doxazosin improves insulin sensitivity in hypertensive patients. Clin Ther. 1993; 15: 829-37.
6. Lehtonen A. Doxazosin effects on insulin and glucose in hypertensive patients. Am Heart J. 1991; 121: 1307-11.
7. Inukai T, Inukai Y, Matsutomo R et al. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism. J Int Med Res. 2004; 32: 206-13.
8. D’Eletto RD, Javitt NB. Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol. 1989; 13(suppl 2): S1-4; discussion S4.
9. Weinberger MH. Antihypertensive therapy and lipids: Paradoxical influences on cardiovascular disease risk. Am J Med. 1986; 80(2A): 64-70. http://doi.org/10.1016/0002-9343(86)90162-2.
10. Ferrara LA, Di Marino L, Russo O et al. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension. 1993; 21: 97-104.
11. Jansen H, Lammers R, Baggen MG et al. Effects of doxazosin on lipids, lipoprotein lipases, and cholesterol synthesis in the golden hamster. J Cardiovasc Pharmacol. 1989; 13(suppl 2): S-9; discussion S9-10.
12. Meredith PA, Elliott HL, Kelman AW et al. Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. Xenobiotica. 1988; 123-9. http://doi.org/10.3109/00498258809055143.
13. Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press. 2009; 18: 74-7.
14. Wykretowicz A, Guzik P, Wysocki H. Doxazosin in the current treatment of hypertension. Expert Opin Pharmacother. 2008; 9: 625-33.
15. Iii KPS, Suplement KP III. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Kardiol Pol. 2013: 27-118. http://doi.org/10.5603/kp.2013.0177.
16. Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-t-moderate hypertension. Doxazosin Investigators’ Study Group. J Cardiovasc Pharmacol. 1999; 33: 791-7.
17. Os I, Stokke HP. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension. Blood Press. 1999; 8: 184-91.
18. Lund-Johansen P, Kirby RS. Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies. Blood Press Suppl. 2003; 1: 5-13.
19. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000; 283: 1967-7.
2. Fulton B, Wagstaff A, Sorkin E. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs. 1995; 49: 295-320.
3. Chung M, Vashi V, Puente J et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999; 48: 678-87.
4. Andersson PE, Johansson J, Berne C et al. Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens. 1994; 8: 219-26.
5. Kageyama S, Yamamoto J, Mimura A et al. Doxazosin improves insulin sensitivity in hypertensive patients. Clin Ther. 1993; 15: 829-37.
6. Lehtonen A. Doxazosin effects on insulin and glucose in hypertensive patients. Am Heart J. 1991; 121: 1307-11.
7. Inukai T, Inukai Y, Matsutomo R et al. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism. J Int Med Res. 2004; 32: 206-13.
8. D’Eletto RD, Javitt NB. Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol. 1989; 13(suppl 2): S1-4; discussion S4.
9. Weinberger MH. Antihypertensive therapy and lipids: Paradoxical influences on cardiovascular disease risk. Am J Med. 1986; 80(2A): 64-70. http://doi.org/10.1016/0002-9343(86)90162-2.
10. Ferrara LA, Di Marino L, Russo O et al. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension. 1993; 21: 97-104.
11. Jansen H, Lammers R, Baggen MG et al. Effects of doxazosin on lipids, lipoprotein lipases, and cholesterol synthesis in the golden hamster. J Cardiovasc Pharmacol. 1989; 13(suppl 2): S-9; discussion S9-10.
12. Meredith PA, Elliott HL, Kelman AW et al. Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. Xenobiotica. 1988; 123-9. http://doi.org/10.3109/00498258809055143.
13. Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press. 2009; 18: 74-7.
14. Wykretowicz A, Guzik P, Wysocki H. Doxazosin in the current treatment of hypertension. Expert Opin Pharmacother. 2008; 9: 625-33.
15. Iii KPS, Suplement KP III. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Kardiol Pol. 2013: 27-118. http://doi.org/10.5603/kp.2013.0177.
16. Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-t-moderate hypertension. Doxazosin Investigators’ Study Group. J Cardiovasc Pharmacol. 1999; 33: 791-7.
17. Os I, Stokke HP. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension. Blood Press. 1999; 8: 184-91.
18. Lund-Johansen P, Kirby RS. Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies. Blood Press Suppl. 2003; 1: 5-13.
19. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000; 283: 1967-7.